In a prior study, we also demonstrated loss of E-cadherin expression in bone metastasis in 24 out of 28 cases (86%).[32] Our results led us to conclude that loss of E-cadherin is a characteristic of progression in prostate cancer. The gene discussed is CDH1; the disease is prostate carcinoma.